Oxy17®: Elevating MRI to monitor cell health

Interview conducted during OMP Investor Conference,  Jan 2008,San Francisco One Med Plac,  www.onemedplace.com, Tel: 212-734-1008

Rockland Technimed Ltd has introduced a new line of breakthrough paradigm shifting and natural Metabolic Magnetic Resonance Imaging  products, namely Oxy-17®.They are used in conjunction with an unaltered MRI scanner (independent of field strength); thereby essentially converting MRI into a Clinical Metabolic Molecular and Physiologic real time Imager for use in drug development, pre-clinical and clinical use. 

A result of over 18 years of research and development effort, during this period of time it has demonstrated its usefulness in tracking all facets of inVivo oxygen metabolism using normally installed MRI scanners. Examples are:

  • Ability to assess tissue viability in cases of neurological and cardiovascular catastrophes such as ( Heart or Stroke attack), or other tissue injury such as Oncology -Cancer.

  • Ability to determine Oxygen Extraction Fraction [OEF] of Tissue such as in stroke at a 1 mm resolution , because they can cross the intact blood brain barrier. [presently can only be done with PET/CT, using a radio-active isotope oxygen-15] at its best resolution of 6 mm.

  • Current PET studies show, with OEF as an indicator the “Golden hour - 3 Hours after onset of Stroke” can now be extended up to 12 hours or more, enabling the clinician and thereby saving lives, reducing disabilities and costs.

  • Ability to track tumor angiogenesis

  • Oxy-17® and OxyMaps™ are useful as " Non Invasive Realtime Tissue Stress Monitor" to evaluate normal and abnormal Oxygen Consumption rates in a biological subject, without any limitations on repeating the test due to dosage and/or other limitations.

 

The Product
Oxy-17® are oxygen metabolic imaging bioscale (TVI-agents) which are injected intravenously prior to Imaging in a standard MRI scanner.
Read More>>

The Proof
Images of cardiac ischemic injury showing identification of tissue at risk (dying ) but viable (at the reversible stage), enabling early clinical intervention. Notice that Oxy-17® TVI results in negative contrast.
Read More>>

FOR INQUIRY:

Click here to request product and order information, or quotation.

Oxy-17® is registered as a Trade Mark of Rockland Technimed Ltd for: Oxygen-based diagnostic agents, preparations and substances for medical purposes, namely, contrast media for medical imaging for use with MRI diagnostic apparatus, and diagnostic scanning agents in the nature of contrast media for use in In-Vivo imaging. Reg # 3,421,019


What the press says :


GRC2012

Brain Energy Metabolism & Blood Flow
August 12-17, 2012
Colby College
Waterville, ME

 


We invite you to visit us at our Exhibit Booth # 335

During -20th Annual Meeting and Exhibition ,

ISMRM May 5-11th, 2012, Melbourne, Australia

Oxy-17 Fifth Users Group International Symposium, St James Club, Montreal, May 10, 2011
Oxy-17 Fourth Users Group International symposium, Sallakapet, Stockholm,2010 
Oxy-17 Third Users Group meeting, The Outriggers Canoe Club, Honolulu, HI, 2009
Oxy-17 Second Users Group meeting , The Albany Club, Toronto, Canada 2008
Oxy-17 First Users Group meeting , The International Club, Berlin. Germany.2007

© Rockland Technimed Limited. All rights reserved

Oxy-17® is registered as a Trade Mark of Rockland Technimed Ltd for: Oxygen-based diagnostic agents, preparations and substances for medical purposes, namely, contrast media for medical imaging for use with MRI diagnostic apparatus, and diagnostic scanning agents in the nature of contrast media for use in In-Vivo imaging. Reg # 3,421,019